What is it about?
My group focuses on new approaches to address loss-of-function in reproductive (ovarian) tissue as experienced with advancing age. This amounts to dialing back the odometer on the high-mileage ovary. We know that older eggs with chromosomal errors are more often harvested from follicles with low perfusion. That link between oxygen delivery and cell fitness matters, because chronic oxygen starvation at the follicle level adversely impacts IVF outcome. Since gonadotropins used during IVF are downstream actors, they arrive far too late to produce any meaningful effect. FertiGen/Regenerative Biology Group are influencing this ovarian microclimate by developing autologous plasma cytokines for injection to optimize oocyte integrity.
Featured Image
Photo by Vaclav on Unsplash
Why is it important?
Perhaps the most fundamental challenges in women's health today are menopause, infertility, and miscarriage. All three are captive to ovarian function and/or gamete competency. While our work with autologous plasma cytokines applications has proved successful across all three domains, refinements continue and more remains to be done.
Perspectives
'Ovarian rejuvenation' holds great promise to re-set the biological clock. This manuscript summarizes key genomic features of this innovative, non-synthetic, hormone-free treatment.
Dr E Scott Sills
Center for Advanced Genetics / FertiGen
Read the Original
This page is a summary of: Ovarian recovery via autologous platelet‐rich plasma: New benchmarks for condensed cytokine applications to reverse reproductive aging, Aging Medicine, February 2022, Wiley,
DOI: 10.1002/agm2.12196.
You can read the full text:
Resources
Contributors
The following have contributed to this page
